Cargando…
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
IMPORTANCE: New York City is a global epicenter for the SARS-CoV-2 outbreak with a significant number of individuals infected by the virus. Patients with multiple myeloma have a compromised immune system, due to both the disease and anti-myeloma therapies, and may therefore be particularly susceptib...
Autores principales: | Hultcrantz, Malin, Richter, Joshua, Rosenbaum, Cara, Patel, Dhwani, Smith, Eric, Korde, Neha, Lu, Sydney, Mailankody, Sham, Shah, Urvi, Lesokhin, Alexander, Hassoun, Hani, Tan, Carlyn, Maura, Francesco, Derkacs, Andriy, Diamond, Benjamin, Rossi, Adriana, Pearse, Roger N., Madduri, Deepu, Chari, Ajai, Kaminetsky, David, Braunstein, Marc, Gordillo, Christian, Davies, Faith, Jagannath, Sundar, Niesvizky, Ruben, Lentzsch, Suzanne, Morgan, Gareth, Landgren, Ola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302217/ https://www.ncbi.nlm.nih.gov/pubmed/32577667 http://dx.doi.org/10.1101/2020.06.09.20126516 |
Ejemplares similares
-
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
por: Hultcrantz, Malin, et al.
Publicado: (2020) -
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
por: Shah, Urvi A., et al.
Publicado: (2021) -
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023) -
P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023) -
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)